Having trouble accessing articles? Reset your cache.

Catching up in beta thalassemia

Why investors think Merganser can compete in beta thalassemia

Despite impressive data from more advanced therapies in beta thalassemia, investors in Merganser Biotech Inc. think there's still a role for the biotech's hepcidin replacement therapy in patients with less severe disease.

The hematology play raised $28 million in a series A round last week led by new investor Novartis Venture Fund. Other new

Read the full 553 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE